Report overview
There are few available adjuvant/neoadjuvant medicines for treatment of high-risk resectable colorectal cancer. Lack of pipeline agents in this setting presents a good opportunity for development of effective treatments that can improve cure rates for resected patients.
This report aims to provide a comprehensive presentation of the global market for Colorectal Cancer Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Colorectal Cancer Drugs. This report contains market size and forecasts of Colorectal Cancer Drugs in global, including the following market information:
Global Colorectal Cancer Drugs Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global Colorectal Cancer Drugs Market Sales, 2018-2023, 2024-2030, (Units)
Global top five Colorectal Cancer Drugs companies in 2022 (%)
The global Colorectal Cancer Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Vascular Endothelial Growth Factor (VEGF) Inhibitors Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Colorectal Cancer Drugs include AB Science, Amgen, Array BioPharma, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Elli Lilly, Roch and Hutchison MediPharma, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Colorectal Cancer Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Colorectal Cancer Drugs Market, by Type, 2018-2023, 2024-2030 ($ Millions) & (Units)
Global Colorectal Cancer Drugs Market Segment Percentages, by Type, 2022 (%)
Vascular Endothelial Growth Factor (VEGF) Inhibitors
Epidermal Growth Factor Receptor (EGFR) Inhibitors
Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors
BRAF or MEK Inhibitors
Tyrosine Kinase (TKI) Inhibitors
Immunomodulators
Global Colorectal Cancer Drugs Market, by Application, 2018-2023, 2024-2030 ($ Millions) & (Units)
Global Colorectal Cancer Drugs Market Segment Percentages, by Application, 2022 (%)
Radiotherapy
Chemotherapy
Global Colorectal Cancer Drugs Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions) & (Units)
Global Colorectal Cancer Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Colorectal Cancer Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Colorectal Cancer Drugs revenues share in global market, 2022 (%)
Key companies Colorectal Cancer Drugs sales in global market, 2018-2023 (Estimated), (Units)
Key companies Colorectal Cancer Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
AB Science
Amgen
Array BioPharma
Bayer
Boehringer Ingelheim
Bristol-Myers Squibb
Elli Lilly
Roch
Hutchison MediPharma
Merck & Co., Inc.
Mologen
Regeneron
Sanofi
Sumitomo Dainippon
Taiho Pharmaceutical
Vaccinogen
Outline of Major Chapters:
Chapter 1: Introduces the definition of Colorectal Cancer Drugs, market overview.
Chapter 2: Global Colorectal Cancer Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Colorectal Cancer Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Colorectal Cancer Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Colorectal Cancer Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
